Skip to main content

Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation

Stock Monitor: Neuralstem Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Idera Pharma, Inc. (NASDAQ: IDRA) ("Idera"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=IDRA as the Company's latest news hit the wire. On April 16, 2018, the Company announced that it has entered into a clinical development support agreement with Pillar Partners Foundation. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Neuralstem, Inc. (NASDAQ: CUR), which also belongs to the Healthcare sector as the Company Idera Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CUR

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Idera Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=IDRA

Pillar Partners Foundation is the philanthropic arm of Pillar Partners, a private investment group committed, under the management of Youssef El Zein and Abude Umari, to the development of proprietary biotechnologies that address large unmet medical needs. Pillar Partners Foundation has made numerous charitable contributions to pioneering medical research in the fields of innate immunity and gene therapy, and to the advancement of the clinical development of immuno-oncology.

The Agreement

Under the terms of the agreement Pillar Partners will provide direct funding to support Idera's three investigator initiated clinical trials to further strategically expand the clinical research of IMO-2125, Idera's toll-like receptor (TLR) 9 agonist into broader melanoma populations and other solid tumors. IMO-2125 received a Fast Track Designation from the US Food and Drug Administration (FDA) in 2017 for the treatment of PD-1 refractory melanoma, in combination with ipilimumab, as well as an Orphan Drug Designation from the FDA for the treatment of melanoma stages IIb to IV.

Idera is currently enrolling a Phase-3 (ILLUMINATE-301) trial of intratumoral administration of IMO-2125, in combination with ipilimumab, in patients with anti-PD-1 refractory metastatic melanoma.

Details of the Three Trials

The three trials within the terms of this agreement are:

  • A Phase-1/2 open label study of intratumoral IMO-2125, in combination with intratumoral ipilimumab and IV nivolumab, in a protocol open to multiple tumor types, including non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma. The principal investigator initiating this trial is Aurélien Marabelle, MD, PhD, Clinical Director of the Cancer Immunotherapy Program at Institut Gustave Roussy, Villejuif, France.
  • A Phase-2 study of intratumoral IMO-2125, in combination with IV pembrolizumab, in patients with NSCLC. The principal investigator initiating this trial is Arafat Tfayli, MD, FRCP, Professor of Clinical Medicine, Director of Research, NK Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
  • A Phase-2 placebo-controlled study of intradermal administration of IMO-2125 in patients with T3/T4 primary melanoma, scheduled to undergo a combined re-excision and sentinel node biopsy procedure. The principal investigators initiating this trial are Bas Koster, MD; Fons van den Eertwegh MD, PhD; and Tanja de Gruijl, PhD, who is Professor of Translational Tumor Immunology and Co-Director of the Cancer Immunology Program at the VU University Medical Center, Cancer Center Amsterdam, The Netherlands.

About Idera Pharmaceuticals, Inc.

Idera is a clinical-stage biopharmaceutical organization focused on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States.

Idera uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. The Company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastro-intestinal disorders. Idera was founded in 1989 and is based in Cambridge, Massachusetts.

Stock Performance Snapshot

April 17, 2018 - At Tuesday's closing bell, Idera Pharma's stock marginally dropped 0.56%, ending the trading session at $1.76.

Volume traded for the day: 566.77 thousand shares.

After yesterday's close, Idera Pharma's market cap was at $329.60 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.9% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.